- Home
- LTH vs LEGN Comparison
LTH vs LEGN Comparison
Compare LTH & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTH | LEGN |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.9B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LTH | LEGN |
|---|---|---|
| Price | $25.56 | $26.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $37.50 | ★ $72.42 |
| AVG Volume (30 Days) | 2.0M | ★ 2.3M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.46 | N/A |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $2,913,442,000.00 | $909,045,000.00 |
| Revenue This Year | $15.07 | $68.83 |
| Revenue Next Year | $10.88 | $51.27 |
| P/E Ratio | $19.93 | ★ N/A |
| Revenue Growth | 15.77 | ★ 74.75 |
| 52 Week Low | $21.49 | $24.11 |
| 52 Week High | $34.99 | $45.30 |
Technical Indicators
Market Signals| Indicator | LTH | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 33.63 |
| Support Level | $24.46 | $26.43 |
| Resistance Level | $27.11 | $28.97 |
| Average True Range (ATR) | 0.68 | 1.50 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 32.48 | 41.06 |
Price Performance
Historical ComparisonAbout LTH Life Time Group Holdings Inc.
Life Time Group Holdings Inc is a lifestyle and leisure brand offering health, fitness, and wellness experiences to a community. It is engaged in designing, building, and operating distinctive and large, multi-use sports and athletic, professional fitness, family recreation, and spa centers in a resort-like environment, principally in residential locations of metropolitan areas in the United States and Canada.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.